Abstract
Nature Biotechnology convenes a group of experts to provide their insights into SARS-CoV-2 vaccines in development.
MeSH terms
-
Animals
-
Betacoronavirus* / genetics
-
Betacoronavirus* / immunology
-
Biotechnology
-
COVID-19
-
COVID-19 Vaccines
-
Clinical Trials, Phase III as Topic
-
Coronavirus Infections / immunology
-
Coronavirus Infections / prevention & control*
-
Coronavirus Infections / virology
-
Disease Models, Animal
-
Drug Development / methods
-
Drug Development / trends
-
Genetic Vectors
-
Global Health
-
Host Microbial Interactions / immunology
-
Humans
-
Immunity, Cellular
-
Immunity, Herd
-
Immunity, Humoral
-
Pandemics / prevention & control*
-
Pneumonia, Viral / immunology
-
Pneumonia, Viral / prevention & control*
-
Pneumonia, Viral / virology
-
SARS-CoV-2
-
Safety
-
Spike Glycoprotein, Coronavirus / genetics
-
Spike Glycoprotein, Coronavirus / immunology
-
Translational Research, Biomedical
-
Vaccines, DNA / genetics
-
Vaccines, DNA / isolation & purification
-
Vaccines, Synthetic / genetics
-
Vaccines, Synthetic / isolation & purification
-
Viral Vaccines* / administration & dosage
-
Viral Vaccines* / isolation & purification
-
Viral Vaccines* / standards
Substances
-
COVID-19 Vaccines
-
Spike Glycoprotein, Coronavirus
-
Vaccines, DNA
-
Vaccines, Synthetic
-
Viral Vaccines
-
spike protein, SARS-CoV-2